Pfizer Boost FY24 Adj. EPS Outlook - Update

RTTNews | hace 202
Stocktwits
Pfizer Boost FY24 Adj. EPS Outlook - Update

(RTTNews) - While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from the prior guidance range of $2.05 and $2.25 per share.

However, the company continues to project revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $2.21 per share on revenues of $60.02 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: PFE
Stocktwits
read more
Pfizer Launches Digital Platform PfizerForAll

Pfizer Launches Digital Platform PfizerForAll

Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews | hace 84
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews | hace 88
Pfizer Boost FY24 Outlook - Update

Pfizer Boost FY24 Outlook - Update

While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews | hace 112
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews | hace 180
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | hace 190
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews | hace 341
Herramientas
Calendario económico
Market Hours
Interest Rates
Holidays Calendar
Mercados Forex
Volatilidad Forex
Correlación Forex
Noticias del Forex
forex analysis
Datos COT
Liquidez
Calculadoras Forex
Heat Map del Forex
Indicators Heatmap
Comunidad
Comunidad
Sistemas
Sistemas más populares
Estrategias
Concursos
Gráficos Forex
Sentimiento Forex
Indicador de perspectivas
Revisiones
Corredores de bolsa
Prop Trading Firms
Servicios SPV
Proveedor de señales
Servicios de programación de AE
Affiliate Programs
Servicios de corretaje PAMM
Servicios de programas de rebaja
Plataformas de trading
Asesores Expertos
Exchanges de Criptomonedas
Trading Courses
Corredores de bolsa
Spreads de Forex
Cotizaciones de los corredores de Forex
Swaps de corredores de Forex
Volumen del corredor Forex
Promociones de corredores Forex Broker News
Plataforma
Widgets
Funciones
API
RSS
Stock Portfolio
Affiliate Software
Gráficos avanzados
Soporte
FAQ
Ayuda
Póngase en contacto con nosotros
¡Informar de un error!
Acerca de
Blog
© 2024 Myfxbook Ltd. Todos los Derechos Reservados.
ADVERTENCIA DE ALTO RIESGO: El comercio de divisas implica un alto nivel de riesgo que puede no ser adecuado para todos los inversores. El efecto de apalancamiento crea un riesgo adicional y una exposición a las pérdidas. Antes de decidirse a operar con divisas, considere cuidadosamente sus objetivos de inversión, su nivel de experiencia y su tolerancia al riesgo. Podría perder una parte o la totalidad de su inversión inicial. No invierta dinero que no puede permitirse perder. Infórmese sobre los riesgos asociados al trading de divisas y pida consejo a un asesor financiero o fiscal independiente si tiene alguna duda. Todos los datos y la información se proporcionan "tal cual" con fines informativos únicamente y no están destinados a fines comerciales o de recomendación. Los resultados pasados no son indicativos de los resultados futuros.